Results Snapshot
Figures in Cr
Standalone - Profit And Loss Results
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
Profit And Loss Analysis Highlights
Net Sales
YoY Growth in year ended Mar 2025 is 32.48% vs 29.17% in Mar 2024
Operating Profit (PBDIT) excl Other Income
YoY Growth in year ended Mar 2025 is 37.69% vs 11.71% in Mar 2024
Interest
YoY Growth in year ended Mar 2025 is 21.67% vs 90.48% in Mar 2024
Profit After Tax
YoY Growth in year ended Mar 2025 is -28.34% vs 62.66% in Mar 2024
Compare Profit and Loss Results of Astrazeneca Phar
Figures in Cr
standalone - Profit And Loss Results
Change(INR)
Change(%)
No of Months
12
12
Operating Income
1,716.00
1,642.00
74.00
4.51%
Less :Inter divisional transfers
0.00
0.00
0.00
0%
Less: Excise
0.00
0.00
0.00
0%
Net Sales
1,716.00
1,642.00
74.00
4.51%
Expenditure (Ex Depriciation)
Stock Adjustments
-332.00
4.00
-336.00
-8,400.00%
Raw Materials Consumed
1,295.00
445.00
850.00
191.01%
Power & Fuel Cost
5.00
48.00
-43.00
-89.58%
Employee Cost
257.00
485.00
-228.00
-47.01%
Operating Expenses
18.00
90.00
-72.00
-80.00%
General and Administration Expenses
-1.00
-1.00
0.00
0.00%
Selling and Distribution Expenses
93.00
11.00
82.00
745.45%
Cost of Software developments
0.00
0.00
0.00
0%
Miscellaneous Expenses
13.00
37.00
-24.00
-64.86%
Expenses Capitalised
0.00
0.00
0.00
0%
Total Expenditure
1,462.00
1,249.00
213.00
17.05%
Operating Profit (PBDIT) excl Other Income
253.00
392.00
-139.00
-35.46%
Other Income
40.00
37.00
3.00
8.11%
Operating Profit (PBDIT)
294.00
429.00
-135.00
-31.47%
Interest
1.00
71.00
-70.00
-98.59%
Profit before Depriciation and Tax
293.00
357.00
-64.00
-17.93%
Depreciation
39.00
126.00
-87.00
-69.05%
Profit Before Taxation & Exceptional Items
253.00
231.00
22.00
9.52%
Exceptional Income / Expenses
0.00
0.00
0.00
0%
Profit Before Tax
156.00
231.00
-75.00
-32.47%
Provision for Tax
40.00
58.00
-18.00
-31.03%
Profit After Tax
115.00
173.00
-58.00
-33.53%
Extraordinary Items
0.00
0.00
0.00
0%
Adj to Profit After Tax
0.00
0.00
0.00
0%
Profit Balance B/F
578.00
594.00
-16.00
-2.69%
Profit Available for appropriations
693.00
767.00
-74.00
-9.65%
Appropriations
693.00
767.00
-74.00
-9.65%
Equity Dividend (%)
1600%
0%
1,600.00
Earnings Per Share
46.3
9
37.30
414.44%
Profit And Loss - Net Sales
Net Sales 1,716.29 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 32.48% vs 29.17% in Mar 2024
Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) 253.97 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 37.69% vs 11.71% in Mar 2024
Profit And Loss - Interest
Interest 1.46 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 21.67% vs 90.48% in Mar 2024
Profit And Loss - Profit After Tax
Profit After Tax 115.74 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is -28.34% vs 62.66% in Mar 2024






